No Data
Piper Sandler Maintains Abivax S.A.(ABVX.US) With Buy Rating, Maintains Target Price $42
Morgan Stanley Maintains Abivax S.A.(ABVX.US) With Hold Rating, Maintains Target Price $12
Morgan Stanley Maintains Abivax S.A.(ABVX.US) With Hold Rating, Cuts Target Price to $12
Abivax Publishes 2025 Financial Calendar
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress
LifeSci Capital Maintains Abivax S.A.(ABVX.US) With Buy Rating, Raises Target Price to $45
